Entropy Neurodynamics Limited (ASX:ENP)
Australia · Delayed Price · Currency is AUD 0.0340
+0.0010 (3.03%)
At close: Mar 13, 2026
Entropy Neurodynamics Revenue
Entropy Neurodynamics had revenue of 1.58M AUD in the twelve months ending December 31, 2025. In the fiscal year ending June 30, 2025, Entropy Neurodynamics had annual revenue of 1.58M with 19.17% growth.
Revenue
1.58M
Revenue Growth
+19.17%
P/S Ratio
34.75
Revenue / Employee
n/a
Employees
n/a
Market Cap
54.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.58M | 254.43K | 19.17% |
| Jun 30, 2024 | 1.33M | - | - |
| Aug 31, 2023 | - | - | - |
| Aug 31, 2022 | - | - | - |
| Aug 31, 2021 | - | - | - |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 61.40M |
| Radiopharm Theranostics | 16.28M |
| Immutep | 7.92M |
| Neurizon Therapeutics | 5.98M |
| Amplia Therapeutics | 5.01M |
| Prescient Therapeutics | 4.27M |
| Imugene | 3.94M |
| Proteomics International Laboratories | 3.21M |